Data protection Impressum

Oncology

HeroSupport, a spin-off from the University Hospitals of Geneva, has obtained CE Mark certification for VENUS SHELL, a personalized 3D-printed breast immobilization system for prone radiotherapy.

HeroSupport receives CE Mark for its VENUS SHELL radiotherapy device

10 March 2026

As life sciences companies navigate increasingly complex global markets, the decision of where to establish or expand international operations has become a strategic one.

Why Life Sciences Companies Choose Switzerland to Scale Internationally

The Fonds pour l’Innovation et le Futur de Genève (FIF) has awarded Seed funding to four early-stage projects in Geneva, reinforcing the canton’s digital and impact-driven innovation ecosystem.

FIF supports four start-ups to reinforce Geneva’s impact-driven innovation ecosystem

24 February 2026

Scientists at the University of Fribourg have identified a molecular mechanism that keeps certain breast cancer cells dormant by stimulating the immune response, opening new therapeutic perspectives.

Fribourg researchers identify breast cancer dormancy mechanism

11 February 2026

Inselspital Bern has performed its 300th CAR-T cell therapy treatment, underscoring Western Switzerland’s role as a leading center for advanced immuno-oncology.

Bern’s Inselspital marks a new era in personalized cancer treatment

8 December 2025

Researchers at CHUV have validated a new stem-cell–based method to study autoimmune diseases in organs such as the brain, offering new insights into conditions like autoimmune encephalitis and multiple sclerosis.

CHUV researchers develop new method to study autoimmune diseases

2 December 2025

A Swiss-led research consortium is developing an AI-powered microfactory capable of producing patient-specific tumor models to revolutionize precision oncology.

ORION: A smart microfactory to accelerate personalized cancer treatments

10 November 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (October 2025)

29 October 2025

The Munich- and Lausanne-based biotech secures Europe’s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.

Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline

29 October 2025

Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.

ADC Therapeutics raises USD 60 million to strengthen oncology portfolio

21 October 2025

1 2 3 4 5 … 10